Sign in
MRK-MERCK & CO INC

Merck & Co. Announces $10 Billion Share Buyback Amid Legal Troubles and Declining Gardasil Sales

Sunday

23 February, 2025

Merck & Co. is navigating turbulent waters with declining Gardasil sales and legal challenges, yet it boldly announces a $10 billion share buyback to bolster investor confidence. Can a strong drug pipeline and a solid dividend yield offset the current volatility and restore faith in the company's future?

article image for MRK

Article Impact Score

0
50
100
Under­perform
Bear­ish
Neu­tral
Bull­ish
Out­perform
69
Key Takeaways
  • Merck & Co. is seen as a strong investment choice despite facing obstacles.
  • A $10 billion share repurchase initiative reflects the firm's confidence in its future.
  • The company offers a quarterly dividend yielding 3.9%, appealing to income investors.
  • Merck's promising pipeline could generate over $50 billion in revenue with regulatory approvals.
  • Strong fundamentals indicate resilience, making it appealing for growth-focused investors.
More on MERCK & CO INC
Read more insights on MERCK & CO INC

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial
home-footer-logo

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.